Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 163Endometrial Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 5Recurrence 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Intraductal, Noninfiltrating 4Triple Negative Breast Neoplasms 3Breast Diseases 3Breast Cancer Metastatic 3Prostatic Neoplasms 2Leiomyosarcoma 2Carcinoma, Lobular 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Polycystic Ovary Syndrome 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pain 1Osteoporosis 1Neoplastic Cells, Circulating 1Neoadjuvant Operable Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphangioleiomyomatosis 1

Interventions

ribociclib 1pembrolizumab 1niraparib 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cystadenocarcinoma, Serous × Letrozole × Clear all
NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡